NASDAQ: BYSIBeyondspring Inc Stock
$1.30+0.22 (+20.37%)
Updated Jun 2, 2023
BYSI Price
$1.30
Fair Value Price
$2.69
Market Cap
$50.70M
52 Week Low
$0.54
52 Week High
$3.45
P/E
-1.53x
P/B
-8.48x
P/S
54.4x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.35M
Earnings
-$33.28M
Gross Margin
100%
Operating Margin
-2,449.96%
Profit Margin
-2,463.3%
Debt to Equity
-8.23
Operating Cash Flow
-$27M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BYSI Overview
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BYSI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BYSI ($1.30) is undervalued by 51.64% relative to our estimate of its Fair Value price of $2.69 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BYSI ($1.30) is significantly undervalued by 51.64% relative to our estimate of its Fair Value price of $2.69 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BYSI due diligence checks available for Premium users.
Be the first to know about important BYSI news, forecast changes, insider trades & much more!
BYSI News
Valuation
BYSI fair value
Fair Value of BYSI stock based on Discounted Cash Flow (DCF)
Price
$1.30
Fair Value
$2.69
Undervalued by
51.64%
BYSI ($1.30) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BYSI ($1.30) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BYSI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BYSI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.53x
Industry
11.51x
Market
52.69x
BYSI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.48x
Industry
5.2x
BYSI's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
BYSI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BYSI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$46.2M
Liabilities
$49.2M
Debt to equity
-8.23
BYSI's short-term assets ($38.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BYSI's long-term liabilities ($41.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BYSI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BYSI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BYSI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BYSI vs Biotech Stocks
Beyondspring Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.